Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC
G. Mountzios,E. Samantas,K. Senghas,E. Zervas,J. Krisam,K. Samitas,F. Bozorgmehr,J. Kuon,S. Agelaki,S. Baka,I. Athanasiadis,L. Gaissmaier,M. Elshiaty,L. Daniello,A. Christopoulou,G. Pentheroudakis,E. Lianos,H. Linardou,K. Kriegsmann,P. Kosmidis,R. El Shafie,M. Kriegsmann,A. Psyrri,C. Andreadis,E. Fountzilas,C. Heussel,F. Herth,H. Winter,C. Emmanouilidis,G. Oikonomopoulos,M. Meister,T. Muley,H. Bischoff,Z. Saridaki,E. Razis,E. Perdikouri,A. Stenzinger,I. Boukovinas,M. Reck,K. Syrigos,M. Thomas,P. Christopoulos JOURNAL OF THORACIC ONCOLOGY（2021）
关键词
predictive biomarkers,Immune checkpoint inhibitors,advanced lung cancer inflammation index
AI 理解论文
溯源树
样例
